Research programme: vascular disruptive agents - Targa Therapeutics

Drug Profile

Research programme: vascular disruptive agents - Targa Therapeutics

Alternative Names: Granzyme B/VEGF; GrB/VEGF; VEGF/rGel; VEGF/rGel-OP

Latest Information Update: 22 Sep 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Peregrine Pharmaceuticals; University of Texas Southwestern Medical Center
  • Developer Targa Therapeutics Corporation
  • Class Antineoplastics; Immunotoxins
  • Mechanism of Action Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Age-related macular degeneration; Diabetic retinopathy; Solid tumours

Most Recent Events

  • 22 Sep 2010 Preclinical development is ongoing in USA
  • 28 Aug 2009 Preclinical development is ongoing
  • 05 Feb 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top